Everything below concerns Dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-11. Numbers and descriptions here follow the published literature rather than marketing material.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Rheumatoid arthritis - autoimmune disease with an unclear cause that manifests as symmetric, erosive synovitis and, occasionally, extraarticular involvement. Systemic lupus erythematosus - chronic, complex autoimmune inflammatory disorder that can affect every organ in the body. Scleroderma and systemic scleroderma - diverse collection of autoimmune fibrosing conditions. Dermatomyositis and polymyositis - autoimmune myopathies that are clinically characterized by extramuscular symptoms, muscle inflammation, proximal muscle weakening, and oftentimes the detection of autoantibodies. Antisynthetase syndrome - multisystematic autoimmune disease associated with inflammatory myositis and interstitial lung disease. Vasculitis - disease that results in blood vessel inflammation. Sjögren's disease - a systemic autoimmune illness that mostly affects the exocrine glands and causes mucosal surfaces, especially those in the mouth and eyes, to become extremely dry. Rheumatic fever - multisystem inflammatory illness that develops after group A streptococcal pharyngitis. Amyloidosis - uncommon condition caused by protein mutations or changes in the body that result in twisted clusters of malformed proteins accumulating on organs and tissues. Osteoarthritis - common articular cartilage degenerative disease linked to hypertrophic bone abnormalities.
(Cm, Z=96): Curium-247, 1.64 × 107 years / 1.56 × 107 years (Am, Z=95): Americium-243; 7,370 years (Bk, Z=97): Berkelium-247; 1.4 × 103 years / 1380 years (Cf, Z=98): Californium-251; 898 years (Es, Z=99): Einsteinium-252; 471.7 days (Fm, Z=100): Fermium-257; 100.5 days (Md, Z=101): Mendelevium-258; 51.5 days (Lr, Z=103): Lawrencium-262; 3.6 hours = 216 minutes (No, Z=102): Nobelium-259; 58 minutes (Rf, Z=104): Rutherfordium-263; approximately 10 minutes (Sg, Z=106): Seaborgium-269; 5 ± 2 minutes (Bh, Z=107): Bohrium-270; approximately 61 seconds
== Clinton administration == During his presidential campaign, Bill Clinton declared that no other president would be tougher on crime. Some scholars have argued that Clinton advanced the war on drugs further than any previous president had imagined possible.
Sources: en.wikipedia.org
trend predicted for rigid elastic spheres. Indeed, the Chapman–Enskog analysis shows that the predicted temperature dependence can be tuned by varying the parameters in various molecular models. A simple example is the Sutherland model, which describes rigid elastic spheres with weak mutual attraction. In such a case, the attractive force can be treated perturbatively, which leads to a simple expression for
== Publishers == George Haven Putnam* (1864), publisher of G. P. Putnam's Sons, son of publisher George Palmer Putnam Henry S. Harper (1888), director of Harper and Brothers, Titanic survivor Bernard H. Ridder (1903), publisher of The St. Paul Dispatch and The Pioneer Press, chairman emeritus of Ridder Publications Alfred Harcourt (1904) and Donald Brace (1904), founders of Harcourt Brace Joseph E. Ridder (1907), publisher of The Journal of Commerce and chairman of Ridder Publications John Neville Wheeler (1908), founder and owner of the North American Newspaper Alliance and Bell Syndicate Harold Latham (1909), editor-in-chief of Macmillan Inc., known for discovering Margaret Mitchell Alfred A. Knopf (1912), founder and chairman of Alfred A. Knopf George T. Delacorte Jr. (1913), founder of Dell Publishing Arthur Hays Sulzberger (1913), publisher of The New York Times Douglas Black (1916), president of Doubleday and Company Bennett Cerf (1920), founder of Random House Donald S. Klopfer* (1922), founder of Random House Richard L. Simon (1920) and Max Lincoln Schuster (1919), co-founders of Simon & Schuster Elliott V. Bell (1925), former editor and publisher of Businessweek David A. Boehm (1934), founder of Sterling Publishing Robert Giroux (1936), chairman of Farrar, Straus and Giroux Ian Ballantine (1938), founder of Ballantine Books Walter B. Pitkin Jr. (1938), editor-in-chief and executive vice president of Bantam Books William D.
In normal skin chondroitin sulfate proteoglycan is mainly found in the basement membrane, but in healing wounds they are up-regulated throughout the granulation tissue especially during the second week of wound repair where they provide a temporary matrix with highly hydrative capacity. Binding of growth factors is an important role of perlecan in wound healing and angiogenesis. Poor wound healing in diabetes mellitus may be related to perlecan expression. High levels of glucose can decrease perlecan expression in some cells, probably through transcriptional and post-transcriptional modification. Wound healing phases, especially granulation, re-epithelization and remodelling exhibit controlled turnover of extracellular matrix components.
Sources: en.wikipedia.org
== Fragrance == Sandalwood oil is used extensively for its woody-floral scent. Sandalwood oil can also, under certain conditions, have a creamy or even pickled aroma. It pairs well with other wood or floral scents such as violet, rose, tuberose, clove, and oakmoss. But since the wood is so rare and expensive, cosmetic companies use synthetic substitutes of similar structure and scent. There are several synthetic odorants with odor similar to sandalwood oil, used as lower-cost alternatives for perfumes, emollients, and skin cleaning agents. Common synthetic substitutes include Bacdanlol, Brahmanol, Ebanol, Firsantol, Sandalore, and Sandaxol. Two of these, Sandalore and Brahmanol, have been found to be agonists of the cutaneous olfactory receptor OR2AT4, with potential therapeutic benefits for wound healing. Natural sandalwood oil, and other synthetic sandalwood odorants, did not have the same effect.
==== Shocks ==== Shocks are short-term deviations from long-term trends that have substantial negative effects on a system, people's state of well-being, assets, livelihoods, safety and ability to withstand future shocks. Shocks impacting on agrifood systems may be covariate (an event that directly affects groups of households, communities, regions or even entire countries) or idiosyncratic (an event that affects individuals or households) and include disasters, extreme climate events, biological and technological events, surges in plant and animal diseases and pests, socio-economic crises and conflicts.
== Characteristics == Various types of kōji are used, including yellow, black, and white. The kōji is stored for two to three days at 30°C under high humidity to allow A. oryzae to grow. In this process, the starch from cereals such as wheat, buckwheat or barley as well as from sweet potato is split into glucose, creating a sweet taste. The amino acids glutamic acid and to a lesser extent also aspartic acid split off from the proteins during fermentation, resulting in a strong umami taste. Depending on the Aspergillus used, culture substrate and culture conditions (temperature, pH value, salt content, humidity), different products are created in terms of composition, flavour and odour. Kōji can be freeze-dried and crushed to produce spores. Dried kōji-spores can be stored and transported light-protected at room temperature.
=== EC 2.7.9: Phosphotransferases with paired acceptors (dikinases) === EC 2.7.9.1: pyruvate, phosphate dikinase EC 2.7.9.2: pyruvate, water dikinase EC 2.7.9.3: selenide, water dikinase EC 2.7.9.4: α-glucan, water dikinase EC 2.7.9.5: phosphoglucan, water dikinase EC 2.7.9.6: rifampicin phosphotransferase
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.